Puma Biotechnology (PBYI) Operating Leases (2019 - 2026)

Puma Biotechnology has reported Operating Leases for 8 years, with the latest figure at $4.5 million in Q1 2026.

• For the quarter ending Q1 2026, Operating Leases changed N/A year-over-year to $4.5 million; the trailing twelve-month figure through Mar 2026 stood at $4.5 million (changed N/A YoY), and the FY2025 full-year result was $4.7 million, up 215.19% from the prior year.
• Operating Leases for Q1 2026 stood at $4.5 million, down from $4.7 million in the prior quarter.
• The five-year high for Operating Leases was $18.7 million in Q1 2022, with the low at $1.5 million in Q4 2024.
• Historically, Operating Leases has averaged $9.6 million across 5 years, with a median of $9.5 million in 2024.
• Annual changes were most pronounced in 2024 — Operating Leases tumbled 78.76% — and 2025, when it soared 215.19%.
• Puma Biotechnology's Operating Leases stood at $11.8 million in 2022, then tumbled by 40.56% to $7.0 million in 2023, then plunged by 78.76% to $1.5 million in 2024, then soared by 215.19% to $4.7 million in 2025, then declined by 3.46% to $4.5 million in 2026.
• The last three Operating Leases figures came in at $4.5 million (Q1 2026), $4.7 million (Q4 2025), and $7.3 million (Q3 2025), per Business Quant data.